Literature DB >> 16616324

Mild hyperhomocysteinemia is associated with a decreased fibrinolytic activity in patients after ST-elevation myocardial infarction.

Walter Stefan Speidl1, Mariam Nikfardjam, Alexander Niessner, Andrea Zeiner, Nelli Jordanova, Gerlinde Zorn, Gerald Maurer, Wolfgang Schreiber, Johann Wojta, Kurt Huber.   

Abstract

BACKGROUND: Elevated homocysteine (Hcy) levels have been associated with increased risk for cardiovascular disease and it has been shown that hyperhomocysteinemia is associated with increased levels of t-PA antigen in individuals without evidence for coronary artery disease (CAD). The aim of this study was to examine if Hcy plasma levels are associated with plasma levels of fibrinolytic factors in patients with CAD and a history of acute myocardial infarction.
METHODS: We measured in 56 patients with CAD, 1 month after their first ST-elevation myocardial infarction, plasma levels of Hcy, the fibrinolytic parameters tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor-type-1 (PAI-1), and t-PA-PAI-1 complexes.
RESULTS: Hcy plasma levels inversely correlated with t-PA activity (r=-0.303, p<0.05). Patients with mild hyperhomocysteinemia (Hcy>15 micromol/L, n=8) showed significantly lower plasma levels of t-PA activity (p<0.05). Regression analysis revealed that out of cardiovascular risk factors and medical treatment only Hcy was significantly associated with t-PA activity.
CONCLUSIONS: Patients with CAD after a first myocardial infarction and hyperhomocysteinemia show a reduced t-PA activity independently from cardiovascular risk factors and medical treatment. Homocysteine lowering therapies may increase fibrinolytic activity and thereby may help to avoid atherothrombotic events in patients with CAD after a first myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16616324     DOI: 10.1016/j.thromres.2006.02.011

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

1.  Homocysteine and long-term recurrent infarction following an acute coronary syndrome.

Authors:  Gema Miñana; Carolina Gil-Cayuela; Lorenzo Fácila; Vicent Bodi; Ernesto Valero; Anna Mollar; Maria Marco; Teresa García-Ballester; Begoña Zorio; Jorge Martí-Cervera; Eduardo Núñez; Francisco J Chorro; Juan Sanchis; Julio Núñez
Journal:  Cardiol J       Date:  2020-12-21       Impact factor: 2.737

2.  The effects of L-cysteine and N-acetyl-L-cysteine on homocysteine metabolism and haemostatic markers, and on cardiac and aortic histology in subchronically methionine-treated Wistar male rats.

Authors:  Sanja Kostić; Žarko Mićovic; Lazar Andrejević; Saša Cvetković; Aleksandra Stamenković; Sanja Stanković; Radmila Obrenović; Milica Labudović-Borović; Dragan Hrnčić; Vladimir Jakovljević; Dragan Djurić
Journal:  Mol Cell Biochem       Date:  2018-06-23       Impact factor: 3.396

3.  Homocysteine has anti-inflammatory properties in a hypercholesterolemic rat model in vivo.

Authors:  Michael Pirchl; Celine Ullrich; Barbara Sperner-Unterweger; Christian Humpel
Journal:  Mol Cell Neurosci       Date:  2012-03-08       Impact factor: 4.314

4.  Admission homocysteine is an independent predictor of spontaneous reperfusion and early infarct-related artery patency before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction.

Authors:  Jing Li; Ying Zhou; Yaowen Zhang; Jingang Zheng
Journal:  BMC Cardiovasc Disord       Date:  2018-06-25       Impact factor: 2.298

Review 5.  Lipoprotein(a)-The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation.

Authors:  Sabina Ugovšek; Miran Šebeštjen
Journal:  Biomolecules       Date:  2021-12-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.